Neuroradiological findings of XXXX leakage in @entity976 . Report of three cases.

@entity1 @entity137 @entity1640 @entity4 @entity134 @entity854 @entity1732 @entity976
Intracystic @entity1732 therapy has been proposed as a treatment for predominantly @entity976 . The risks of using this therapy, however, have not been clearly identified. The authors report on three @entity1 treated with intracystic @entity1732 who developed initially mild symptoms during their course of therapy. They describe the neuroimaging findings from computed tomography (CT) scans and magnetic resonance (MR) images and the medical management of these three cases. Two @entity1 in whom @entity976 was recently diagnosed and one @entity1 with recurrent @entity976 were treated with a course of 3 mg of intracystic @entity1732 three times a week for 5 weeks, followed by once every week for 10 weeks. All @entity1 had a negative reservoir permeability test prior to beginning intracystic @entity1732 therapy. @entity1 were asymptomatic or had mild symptoms at the time of neuroimaging. Magnetic resonance images revealed extensive vasogenic @entity4 surrounding the cyst in all three @entity1 , consistent with signs of @entity1732 leakage. The @entity4 occurred near the time of the 12th injection in two @entity1 , and at the end of treatment in the remaining @entity1 . Subsequently, two @entity1 developed further symptoms suggestive of @entity1640 . These two @entity1 received corticosteroids, leading to a rapid and sustained clinical improvement. Follow-up serial MR images showed a progressive regression of the surrounding @entity4 . Neuroimaging documentation of @entity1732 @entity137 has been described mainly in adults experiencing severe @entity137 . There was no correlation between clinical symptoms and the extent of @entity4 in these three @entity1 . An MR image provides a higher resolution than CT scans for evaluating the adjacent cerebral structures and is very sensitive in detecting @entity854 , even in asymptomatic @entity1 . @entity1732 therapy requires close clinical monitoring. Imaging evaluation should be performed using MR imaging during treatment to ensure the safety of the therapy. In the authors' experience, the @entity137 to @entity1732 was transient. Management of the @entity137 using high-dose @entity134 administration appears to contribute to controlling the @entity1732 -induced inflammatory process.
